 Breelyn Wilky
Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 16 | 2022 | 137 | 5.050 |
Why?
| | Soft Tissue Neoplasms | 8 | 2022 | 90 | 2.420 |
Why?
| | Fibromatosis, Aggressive | 4 | 2023 | 18 | 1.920 |
Why?
| | Immunotherapy | 10 | 2023 | 474 | 1.830 |
Why?
| | Molecular Targeted Therapy | 6 | 2019 | 347 | 1.530 |
Why?
| | Sarcoma, Alveolar Soft Part | 2 | 2023 | 7 | 1.510 |
Why?
| | Hemangiosarcoma | 2 | 2021 | 18 | 1.340 |
Why?
| | Bone Neoplasms | 7 | 2023 | 194 | 1.270 |
Why?
| | Gastrointestinal Stromal Tumors | 4 | 2022 | 43 | 1.140 |
Why?
| | Biomarkers, Tumor | 8 | 2022 | 1040 | 1.080 |
Why?
| | Antineoplastic Agents | 8 | 2023 | 1879 | 1.050 |
Why?
| | Precision Medicine | 2 | 2019 | 336 | 0.990 |
Why?
| | Pyrimidines | 2 | 2018 | 376 | 0.840 |
Why?
| | Circulating Tumor DNA | 2 | 2022 | 22 | 0.830 |
Why?
| | Sulfonamides | 2 | 2018 | 445 | 0.810 |
Why?
| | Leiomyosarcoma | 1 | 2022 | 26 | 0.810 |
Why?
| | Immunomodulation | 2 | 2019 | 84 | 0.660 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 1355 | 0.650 |
Why?
| | Antineoplastic Agents, Immunological | 3 | 2019 | 152 | 0.630 |
Why?
| | Salvage Therapy | 1 | 2019 | 127 | 0.610 |
Why?
| | Neoplasms | 4 | 2023 | 2097 | 0.590 |
Why?
| | DEAD-box RNA Helicases | 1 | 2015 | 56 | 0.490 |
Why?
| | Neovascularization, Pathologic | 1 | 2017 | 281 | 0.490 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2015 | 83 | 0.480 |
Why?
| | Sarcoma, Ewing | 1 | 2015 | 64 | 0.470 |
Why?
| | Chondrosarcoma | 3 | 2023 | 12 | 0.470 |
Why?
| | Humans | 46 | 2023 | 114624 | 0.450 |
Why?
| | Prognosis | 7 | 2022 | 3328 | 0.450 |
Why?
| | Solitary Fibrous Tumors | 1 | 2013 | 3 | 0.450 |
Why?
| | Thoracic Neoplasms | 1 | 2013 | 32 | 0.440 |
Why?
| | Liposarcoma | 2 | 2023 | 26 | 0.420 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2018 | 858 | 0.410 |
Why?
| | Magnetic Resonance Imaging | 3 | 2021 | 3039 | 0.380 |
Why?
| | Brain Neoplasms | 1 | 2019 | 979 | 0.380 |
Why?
| | Giant Cell Tumor of Bone | 2 | 2021 | 6 | 0.370 |
Why?
| | Combined Modality Therapy | 5 | 2019 | 1121 | 0.350 |
Why?
| | Bone Density Conservation Agents | 2 | 2021 | 62 | 0.350 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 2 | 2019 | 40 | 0.300 |
Why?
| | Treatment Outcome | 8 | 2021 | 9084 | 0.260 |
Why?
| | Indazoles | 2 | 2018 | 58 | 0.250 |
Why?
| | Isocitrate Dehydrogenase | 2 | 2015 | 38 | 0.240 |
Why?
| | Liquid Biopsy | 2 | 2022 | 6 | 0.240 |
Why?
| | Imidazoles | 2 | 2015 | 208 | 0.230 |
Why?
| | Denosumab | 2 | 2021 | 7 | 0.230 |
Why?
| | Adult | 14 | 2023 | 30528 | 0.230 |
Why?
| | Protein Kinase Inhibitors | 2 | 2021 | 785 | 0.230 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2023 | 26 | 0.220 |
Why?
| | Cancer Vaccines | 3 | 2019 | 137 | 0.220 |
Why?
| | Mutation | 4 | 2022 | 3344 | 0.210 |
Why?
| | Postoperative Complications | 1 | 2013 | 2128 | 0.210 |
Why?
| | Tetrahydronaphthalenes | 1 | 2023 | 31 | 0.210 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2019 | 663 | 0.210 |
Why?
| | Survival Rate | 2 | 2019 | 1644 | 0.200 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 92 | 0.200 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2019 | 195 | 0.200 |
Why?
| | Tumor Microenvironment | 3 | 2019 | 430 | 0.200 |
Why?
| | Giant Cell Tumor of Tendon Sheath | 1 | 2021 | 2 | 0.190 |
Why?
| | Translocation, Genetic | 2 | 2019 | 94 | 0.190 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2021 | 13 | 0.190 |
Why?
| | Quinazolines | 1 | 2023 | 240 | 0.190 |
Why?
| | Clinical Trials, Phase II as Topic | 3 | 2019 | 59 | 0.190 |
Why?
| | beta Catenin | 1 | 2022 | 219 | 0.180 |
Why?
| | Neoplasm Staging | 4 | 2018 | 1167 | 0.170 |
Why?
| | Osteoblasts | 1 | 2021 | 106 | 0.170 |
Why?
| | Chromosomes, Human, Pair 7 | 1 | 2019 | 15 | 0.170 |
Why?
| | Chromosomes, Human, Pair 12 | 1 | 2019 | 20 | 0.170 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2019 | 21 | 0.170 |
Why?
| | Oncogene Fusion | 1 | 2019 | 9 | 0.170 |
Why?
| | Chemoradiotherapy | 1 | 2021 | 188 | 0.170 |
Why?
| | Gene Fusion | 1 | 2019 | 18 | 0.170 |
Why?
| | Sarcoma, Synovial | 1 | 2019 | 11 | 0.170 |
Why?
| | Retrospective Studies | 5 | 2022 | 12542 | 0.170 |
Why?
| | Female | 13 | 2023 | 59466 | 0.170 |
Why?
| | Middle Aged | 10 | 2021 | 26719 | 0.170 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 439 | 0.170 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2019 | 86 | 0.160 |
Why?
| | Gene Amplification | 1 | 2019 | 95 | 0.160 |
Why?
| | Animals | 9 | 2021 | 31695 | 0.160 |
Why?
| | Tumor Escape | 1 | 2019 | 35 | 0.160 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 522 | 0.160 |
Why?
| | Male | 12 | 2022 | 55555 | 0.150 |
Why?
| | Costimulatory and Inhibitory T-Cell Receptors | 1 | 2018 | 7 | 0.150 |
Why?
| | Neurofibrosarcoma | 1 | 2018 | 2 | 0.150 |
Why?
| | Carcinogenesis | 1 | 2019 | 177 | 0.150 |
Why?
| | Antigens, Neoplasm | 1 | 2019 | 221 | 0.150 |
Why?
| | Follow-Up Studies | 2 | 2019 | 4411 | 0.150 |
Why?
| | Immunotherapy, Adoptive | 1 | 2019 | 183 | 0.150 |
Why?
| | Hematology | 1 | 2017 | 13 | 0.150 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2019 | 226 | 0.140 |
Why?
| | Actins | 1 | 2019 | 381 | 0.140 |
Why?
| | Radiography | 2 | 2021 | 812 | 0.140 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 718 | 0.140 |
Why?
| | Rhabdoid Tumor | 1 | 2018 | 80 | 0.140 |
Why?
| | T-Lymphocyte Subsets | 1 | 2019 | 383 | 0.140 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 931 | 0.140 |
Why?
| | Cell Line, Tumor | 4 | 2015 | 2710 | 0.130 |
Why?
| | Simulation Training | 1 | 2017 | 61 | 0.130 |
Why?
| | Drug Discovery | 1 | 2017 | 123 | 0.130 |
Why?
| | Glutarates | 1 | 2015 | 6 | 0.130 |
Why?
| | Benzeneacetamides | 1 | 2015 | 7 | 0.130 |
Why?
| | Medical Oncology | 1 | 2017 | 229 | 0.130 |
Why?
| | Disease Management | 1 | 2019 | 560 | 0.120 |
Why?
| | Azepines | 1 | 2015 | 75 | 0.120 |
Why?
| | Drug Monitoring | 1 | 2016 | 184 | 0.120 |
Why?
| | Ovarian Neoplasms | 1 | 2019 | 388 | 0.120 |
Why?
| | T-Lymphocytes | 2 | 2019 | 1736 | 0.120 |
Why?
| | Fellowships and Scholarships | 1 | 2017 | 227 | 0.120 |
Why?
| | Aged | 7 | 2021 | 19061 | 0.120 |
Why?
| | Macrophages | 1 | 2021 | 1261 | 0.120 |
Why?
| | Receptor, IGF Type 1 | 1 | 2014 | 58 | 0.120 |
Why?
| | Gene Knockdown Techniques | 1 | 2015 | 299 | 0.120 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2014 | 68 | 0.110 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2017 | 358 | 0.110 |
Why?
| | Apoptosis | 3 | 2023 | 2362 | 0.110 |
Why?
| | Paired Box Transcription Factors | 1 | 2014 | 36 | 0.110 |
Why?
| | Chordoma | 1 | 2013 | 11 | 0.110 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2018 | 636 | 0.110 |
Why?
| | Membrane Proteins | 1 | 2019 | 1018 | 0.110 |
Why?
| | Antibodies, Monoclonal | 2 | 2023 | 1262 | 0.110 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 299 | 0.110 |
Why?
| | Benzimidazoles | 1 | 2014 | 138 | 0.110 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2084 | 0.110 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2013 | 82 | 0.110 |
Why?
| | Rhabdomyosarcoma | 1 | 2014 | 54 | 0.110 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2015 | 698 | 0.110 |
Why?
| | Young Adult | 6 | 2021 | 10455 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2015 | 1141 | 0.110 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2013 | 180 | 0.110 |
Why?
| | Forkhead Transcription Factors | 1 | 2014 | 170 | 0.100 |
Why?
| | Disease-Free Survival | 1 | 2014 | 620 | 0.100 |
Why?
| | Aged, 80 and over | 4 | 2019 | 6344 | 0.100 |
Why?
| | Enzyme Inhibitors | 1 | 2015 | 750 | 0.100 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2014 | 179 | 0.100 |
Why?
| | Connective Tissue | 2 | 2022 | 36 | 0.100 |
Why?
| | Sirolimus | 1 | 2013 | 181 | 0.100 |
Why?
| | Doxorubicin | 1 | 2013 | 285 | 0.100 |
Why?
| | Angiogenesis Inhibitors | 1 | 2013 | 214 | 0.100 |
Why?
| | Curriculum | 1 | 2017 | 819 | 0.090 |
Why?
| | Immunohistochemistry | 3 | 2021 | 1629 | 0.090 |
Why?
| | NF-kappa B | 1 | 2013 | 638 | 0.080 |
Why?
| | Consensus | 2 | 2022 | 537 | 0.080 |
Why?
| | Clinical Trials, Phase I as Topic | 2 | 2019 | 45 | 0.080 |
Why?
| | Mice | 4 | 2021 | 14860 | 0.080 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2013 | 1214 | 0.070 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2019 | 111 | 0.070 |
Why?
| | Neoplasm Grading | 2 | 2018 | 242 | 0.070 |
Why?
| | Adolescent | 4 | 2021 | 17831 | 0.060 |
Why?
| | Cohort Studies | 1 | 2014 | 4894 | 0.060 |
Why?
| | Disease Progression | 2 | 2022 | 2380 | 0.060 |
Why?
| | Frameshift Mutation | 1 | 2023 | 27 | 0.060 |
Why?
| | Activating Transcription Factor 4 | 1 | 2023 | 18 | 0.050 |
Why?
| | Proteasome Inhibitors | 1 | 2023 | 40 | 0.050 |
Why?
| | Cell Differentiation | 2 | 2021 | 1700 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2023 | 56 | 0.050 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2023 | 133 | 0.050 |
Why?
| | Valine | 1 | 2023 | 72 | 0.050 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2023 | 72 | 0.050 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2023 | 122 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2022 | 90 | 0.050 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2022 | 102 | 0.050 |
Why?
| | Cytokines | 2 | 2019 | 1840 | 0.040 |
Why?
| | Prospective Studies | 2 | 2022 | 6217 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 531 | 0.040 |
Why?
| | Mice, Nude | 1 | 2021 | 630 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2021 | 440 | 0.040 |
Why?
| | T-Cell Antigen Receptor Specificity | 1 | 2019 | 41 | 0.040 |
Why?
| | HLA-A Antigens | 1 | 2019 | 49 | 0.040 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2023 | 445 | 0.040 |
Why?
| | Cell Lineage | 1 | 2021 | 309 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2023 | 1660 | 0.040 |
Why?
| | Oncolytic Viruses | 1 | 2018 | 5 | 0.040 |
Why?
| | Oncolytic Virotherapy | 1 | 2018 | 8 | 0.040 |
Why?
| | Margins of Excision | 1 | 2018 | 29 | 0.040 |
Why?
| | Organ Sparing Treatments | 1 | 2018 | 31 | 0.040 |
Why?
| | SMARCB1 Protein | 1 | 2018 | 17 | 0.040 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2018 | 182 | 0.040 |
Why?
| | SEER Program | 1 | 2018 | 196 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 130 | 0.040 |
Why?
| | Syndrome | 1 | 2018 | 333 | 0.040 |
Why?
| | Pedigree | 1 | 2018 | 460 | 0.030 |
Why?
| | Models, Molecular | 1 | 2021 | 1369 | 0.030 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2017 | 56 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2021 | 2218 | 0.030 |
Why?
| | Surgical Procedures, Operative | 1 | 2018 | 207 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2019 | 615 | 0.030 |
Why?
| | Immune System | 1 | 2017 | 172 | 0.030 |
Why?
| | Risk | 1 | 2018 | 812 | 0.030 |
Why?
| | Population Surveillance | 1 | 2018 | 392 | 0.030 |
Why?
| | Incidence | 1 | 2021 | 2311 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2021 | 2186 | 0.030 |
Why?
| | PAX3 Transcription Factor | 1 | 2014 | 11 | 0.030 |
Why?
| | Forkhead Box Protein O1 | 1 | 2014 | 15 | 0.030 |
Why?
| | Radiation | 1 | 2014 | 24 | 0.030 |
Why?
| | Mutation, Missense | 1 | 2015 | 293 | 0.030 |
Why?
| | Cell Cycle Checkpoints | 1 | 2014 | 84 | 0.030 |
Why?
| | Education, Medical, Graduate | 1 | 2017 | 368 | 0.030 |
Why?
| | Rats | 1 | 2021 | 4958 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2013 | 181 | 0.030 |
Why?
| | Chondrocytes | 1 | 2015 | 199 | 0.030 |
Why?
| | Program Evaluation | 1 | 2017 | 822 | 0.030 |
Why?
| | Quality of Life | 1 | 2023 | 2353 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2021 | 3531 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1691 | 0.020 |
Why?
| | Phenotype | 1 | 2019 | 2796 | 0.020 |
Why?
| | Communication | 1 | 2017 | 744 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 993 | 0.020 |
Why?
| | Adaptation, Physiological | 1 | 2014 | 483 | 0.020 |
Why?
| | Recurrence | 1 | 2013 | 935 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 3408 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1183 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2016 | 2762 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2013 | 1842 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1760 | 0.020 |
Why?
| | Child | 2 | 2019 | 18404 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2013 | 1518 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 1879 | 0.020 |
Why?
| | Child, Preschool | 1 | 2019 | 9108 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 4620 | 0.020 |
Why?
| | Infant | 1 | 2018 | 7959 | 0.020 |
Why?
|
|
Wilky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|